CB-103 New

Product Description

CB-103 is a highly specific protein-protein interaction (PPI) inhibitor that interferes with the interaction between the active intracellular domains of Notch receptors (NICD) and the CSL transcription factor complex. In combination with ICI 182,780 (Cat. No. 1047), CB-103 arrests the growth of mouse xenografts. In mouse models, it displays potent tumor growth inhibition and delayed tumor relapse when combined with Taxol (Cat. No. 1097). CB-103 inhibits differentiation of mural cells by downregulating Notch pathway. CB-103 is orally bioavailable.

Solubility

Preparing Stock Solutions for CB-103

The following data is based on the product molecular weight 242.30

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	4.13 mL	20.64 mL	41.27 mL
5 mM	0.83 mL	4.13 mL	8.25 mL
10 mM	0.41 mL	2.06 mL	4.13 mL
50 mM	0.08 mL	0.41 mL	0.83 mL

Calculators

Background References

References are publications that support the biological activity of the product.

• Gastfriend Notch3 directs differentiation of brain mural cells from human pluripotent stem cell-derived neural crest. Sci.Adv. 2024 PMID: 38306433
• Vigolo The efficacy of CB-103, a first-in-class transcriptional Notch inhibitor, in preclinical models of breast cancer. Cancers 2023 PMID: 37568775